ABSTRACr A rapid, simple method for measuring bronchial responsiveness to inhaled histamine is described. The method was used to obtain dose response curves in 50 atopic subjects with varying respiratory and nasal symptoms. The cumulative dose of histamine which caused a 20% fall in the one second forced expiratory volume (PD2>FEV.) varied between 0*046 and greater than 39 ,umol and correlated with the severity of symptoms. The reproducibility of the PD2,FEv,, determined from duplicate measurements in 15 subjects with varying degrees of bronchial responsiveness was found to be satisfactory. When the PD2OFEV, from this rapid method was compared with that obtained from the dosimeter method no significant difference was found. The dose delivered by this method was shown to be cumulative. May 1983 drive the nebuliser, so the equipment is cumbersome.
Increased bronchial responsiveness to histamine and methacholine is one of the hallmarks of asthma. Measurement of the degree of hyperresponsiveness is an important tool in the clinical management of patients with asthma, in epidemiological studies, and in research relating to the causes of asthma. The degree of hyperresponsiveness has been shown to correlate well with the severity of asthma.1 2 Although several techniques for the measurement of bronchial hyperresponsiveness have been described, two are used widely. The first, described by Cockcroft et (De Vilbiss Co, Pennsylvania) were used to administer saline or histamine by hand. To determine the output of each nebuliser, 1 ml saline was placed in the nebuliser, the stoppers were placed in the holes, and the unit was weighed. The stoppers were removed and the bulb of the nebuliser was squeezed firmly 10 times. With the stopper replaced to reduce evaporation the unit was reweighed. This procedure was repeated 10 times for each nebuliser to determine the mean volume delivered per squeeze.
After baseline FEVy had been established the subject inhaled three breaths of normal saline from the first nebuliser. The mouthpiece of the nebuliser was placed between the teeth of the subject, who exhaled to slightly below functional residual capacity (FRC) and then inhaled slowly over one to two seconds towards total lung capacity (TLC), where the breath was held for three seconds. At the beginning of inspiration the operator gave the bulb of the nebuliser one firm squeeze. The FEV, was measured after 60 seconds and the higher of two values that were reproducible to within 100 ml was recorded.
The subject then took one inhalation of 3-1 mg/ml histamine, as listed in the dose schedule in table 2. This was considered to be equivalent to 0 03 ,umol histamine since the mean output of the nebuliser was 0 003 ml per squeeze. The FEV, was recorded 60 seconds after each dose and followed immediately by the next dose. When a dose required more than one inhalation, these were given in consecutive breaths. The With the dosimeter set to give a nebulisation time of 0.6 seconds, the nebuliser was weighed before and after five nebulisations. The procedure was repeated 10 times. After baseline FEV, had been measured the subject inhaled five breaths of normal saline from the nebuliser attached via a nebulisation dosimeter (Rosenthal-French, USA) to compressed air at 20 lb/in2 (138 kPa). Inhalations were taken slowly from slightly below FRC towards TLC with a nebulisation time of 0-6 seconds. As with the hand operated technique the inhalation time was one to two seconds followed by a breath hold of three seconds. FEV, was measured 60 seconds later. The challenge began with five breaths of 0.3 mg/ml histamine (0-006 umol histamine) and continued with doubling concentrations to 10 mg/ml. The challenge was stopped when the FEV1 had fallen by more than 20% or when the maximum dose had been reached. The study took 25-30 minutes to complete. Bronchodilator aerosol was used to aid recovery.
EXPRESSION AND ANALYSIS OF DATA
On the basis of the estimated volume delivered by the nebuliser and the known concentration of the solution, the dose of histamine delivered to the mouth of the subject was calculated in terms of ,mmoles of the salt. Response was measured as per- In seven subjects the change in FEV, after the final dose of histamine in the first study was compared with the change in FEV1 after the total cumulative dose of histamine given as a single dose (fig 3) . There was no significant difference between 
Discussion
This study has shown that this simple, rapid method for measuring bronchial responsiveness produces reproducible results similar to those obtained with the standard dosimeter method. Bronchial responsiveness to histamine, as measured by this method, correlates well with the clinical severity of symptoms, as shown previously for other methods. ' 2 To compare this method with the dosimeter method it was necessary to estimate the volume of solution delivered from the two types of nebuliser and calculate the actual dose of histamine delivered. This was done so that in future it will be possible to compare the potency of histamine with that of other agonists with different molecular weights, such as methacholine. We have shown that the effects of the doses of histamine delivered by this method are cumulative. In practice, this has made it possible to decrease the amount of time taken to administer the challenge by combining some of the doses. On some occasions doses 3 and 4 and doses 5 and 6 (both pairs requiring one inhalation followed by two inhalations) were combined in a single dose of three inhalations of the appropriate concentration. The total dose delivered remained unchanged. We emphasise that this was done only in subjects with no history suggesting heightened bronchial responsiveness and only when they had shown no response to the previous dose. Since it is important to plot a dose response curve so that the level of responsiveness can be accurately determined, doses were combined only when it was clear that this would not jeopardise our ability to get at least three points on the curve.
Examination of the time course of the response to histamine showed that the response was maximal at 60 seconds and maintained for at least three minutes (fig 4) . The FEV, should be measured after 60 seconds and provided that the next dose is given no more than three minutes after the previous one the effect is shown to be cumulative. 
